Doheny Eye Institute

02/05/2026

Our retina specialists were proud to contribute to the global conversation at Hawaiian Eye and Retina 2026 on the Big Island, Hawaii.

Dr. Srinivas R. Sadda shared expertise across multiple sessions, from acquired vitelliform lesions in AMD and the evolving relationship between anti-VEGF therapy and atrophy, to expert panels focused on imaging, case management, and emerging optogenetic therapies.

Dr. Michael Ip helped lead dynamic discussions on diabetic retinopathy, retinal vascular disease, and real-world decision-making for retinal vein occlusion, offering practical insights clinicians can apply in everyday care. We’re honored to see Doheny-affiliated faculty advancing dialogue, collaboration, and innovation in retina on an international stage.

02/02/2026

We are proud to share that Srinivas Sadda, MD has been selected to receive the Asia-Pacific Academy of Ophthalmology (APAO) Senior Achievement Award.

This distinguished honor recognizes Dr. Sadda’s longstanding commitment and invaluable contributions to APAO scientific programs, which have helped advance ophthalmic education and enriched the global ophthalmology community. The award will be presented later this week during the 41st APAO Congress, taking place February 5–8, 2026, in Hong Kong.

Congratulations to Dr. Sadda on this well-deserved recognition!

01/31/2026

The 4th Annual Doheny-UCLA International Retina Symposium 👁️ was held today. It was a day full of world-class science, and real camaraderie.

What stood out most was the collaborative spirit within the UCLA Department of Ophthalmology. From thoughtful case discussions to moments of good-natured challenge, learning felt truly shared. A highlight was watching Dr. David Sarraf test the faculty with complex and intriguing retinal cases, sparking lively dialogue and sharp clinical insight.

With international perspectives from Sobha Sivaprasad, MD, FRCOpth, of Moorfields Eye Hospital and Mark W. Johnson, MD, of the University of Michigan, the day delivered practical takeaways, fresh thinking, and a clear focus on better care for patients with retinal disease.

A special shout out to Doheny’s Dr. Michael Ip for putting together an excellent program and Dr. Giulia Corradetti on her first stint as Doheny CME course co-director.

01/29/2026

In recognition of Glaucoma Awareness Month, Doheny-UCLA glaucoma specialist Brian A. Francis, MD, MS, shares insights on what’s next in glaucoma care in a recent interview with Glaucoma Physician.

From advances in imaging and genetics to emerging approaches in neuroprotection and patient-centered care, Dr. Francis looks ahead at how glaucoma management continues to evolve.

To read or see the full interview: https://www.glaucomaphysician.net/issues/2026/january/looking-ahead-during-glaucoma-awareness-month/

Brian A. Francis, MD, discusses emerging diagnostics, neuroprotection, and patient-centered advances shaping the future of glaucoma management.

01/28/2026

Happening today at UCLA Ophthalmology Grand Rounds 👁️✨

We’re excited to spotlight Daniel Rootman, MD, Doheny-affiliated oculoplastics expert and Clinical Professor of Ophthalmology at UCLA, moderating an outstanding program focused on complex orbital and ophthalmic plastic surgery cases.

From corneal neurotization to diagnostic challenges beyond Graves’ disease, today’s case presentations and specialty service program reflect the depth, nuance, and innovation shaping oculoplastics care.

📍 RPB Auditorium, UCLA Stein Eye Institute
🕟 Wednesday, January 28 | 4:30 PM

Can’t join in person? Attend virtually via Zoom:
🔗 https://uclahs.zoom.us/j/94319971957

Meeting ID: 943 1997 1957 | Passcode: 008840

This is a must-attend afternoon of learning and discussion!

01/17/2026

Advancing care for patients with retinal vein occlusion.

Join this Grand Rounds–style CME activity, Transforming Care Through Next-Generation Therapies in Retinal Diseases, an expansion of the Vision RELIEF: No Eyes Left Behind initiative. Chaired by Dr. Srinivas Sadda, this program explores how next-generation anti-VEGF therapies may help reduce treatment burden while improving outcomes in RVO.

Through evidence review and case-based discussion, participants will examine efficacy, safety, dosing strategies, and patient selection to better optimize real-world care.

✔️ 1.0 AMA PRA Category 1 Credit™
✔️ 1.0 ANCC contact hour
✔️ No fee to participate

Details and access here:

This Grand Round series will overview current barriers in the treatment of RVO, focusing on the role that next-generation anti-VEGF agents have in addressing these barriers and improving outcomes. The rationale, efficacy, and safety of next-generation anti-VEGF agents will be covered, and case-based...

01/16/2026

January is Glaucoma Awareness Month. Glaucoma can develop without symptoms, making routine eye exams essential. Early diagnosis and personalized care play a critical role in protecting vision. We’re proud to highlight our Doheny glaucoma specialists who are advancing glaucoma care every day.

Protecting vision starts with awareness and expert care.

01/13/2026

Today’s Work-in-Progress meeting featured Peng Shang, PhD, who shared new insights on how the Complement Factor H (Y402H) polymorphism linked to age-related macular degeneration may alter retinal fatty acid metabolism. These sessions spark thoughtful, collegial dialogue and highlight the innovative research happening every day at Doheny Eye Institute as we work to advance vision science.

01/09/2026

Today’s Doheny Distinguished Lecture Series featured an outstanding presentation by Connie Cepko, PhD, Bullard Professor of Genetics and Neuroscience at Harvard Medical School and Investigator at the Howard Hughes Medical Institute.

Dr. Cepko’s talk, “Gene-Agnostic Gene Therapy to Preserve Vision,” offered a compelling look at emerging strategies to protect retinal cells and advance treatments for inherited retinal disease. We’re grateful to everyone who joined us in person and on Zoom for a thoughtful and inspiring discussion.

01/08/2026

A tiny enzyme may play an unexpected role in how diabetic eye disease begins.

Doheny researchers Mahesh Agarwal, Sathishkumar Chandrakumar, Irene Santiago Tierno, Emma Lessieur, and Kaustabh Ghosh recently published new findings in Diabetes that help explain how diabetic eye disease may start long before symptoms appear.

Their research reveals how excess lysyl oxidase (LOX), a naturally occurring enzyme, can stiffen retinal blood vessels and overactivate immune cells, setting off early damage that leads to diabetic retinopathy. By uncovering this chain reaction, the team is opening the door to earlier detection and future therapies aimed at protecting vision before it’s lost.

🔬 Discoveries like this bring us closer to preventing vision loss, not just treating it. Read more at doheny.org.

01/07/2026

Today marks one year since the fires that deeply affected our region.

We pause to remember those who lost homes, businesses, and a sense of normalcy, and to thank the first responders and neighbors who showed extraordinary courage and care. We recognize that recovery takes time, and we continue to hold our community close.

One year later, we remember. We stand with all who lost so much and with those still rebuilding.

01/06/2026

Today we celebrated 40 incredible years of service as Carmen Sanchez officially retired from Doheny Eye Institute.

Throughout the luncheon, one message came through loud and clear: Carmen will be deeply missed. For four decades, she took such genuine care of our faculty and staff, always making sure everyone felt supported, welcomed, and looked after.

Thank you, Carmen, for your dedication, kindness, and the lasting impact you’ve made on the Doheny community. Wishing you a joyful and well-earned retirement. You’ll always be part of the Doheny family 💜